Market Analysis - Biosciencecongress-2017
The growth of Bioscience industry as per Transparency Market Research is estimated to observe substantial growth during 2010 and 2017 as investments from around the world are anticipated to rise, especially from emerging economical regions of the world. The report states that the global market for biotechnology, studied according to its application areas, shall grow at an average annual growth rate of CAGR 11.6% from 2012 to 2017 and reach a value worth USD 414.5 billion by the end of 2017. This market was valued approximately USD 216.5 billion in 2011. The market of bio agriculture, combined with that of bio seeds, is projected to reach a value worth USD 27.46 billion by 2018. The field of biopharmaceuticals dominated the global biotechnology market and accounted for 60% shares of it in the year 2011. Many biotechnological industries flourished by the technological advancements leading to new discoveries and rising demands from the pharmaceutical and agricultural sectors.
Bioscience market in USA
Bioscience market in Europe
Bioscience Market in Asia
Bioscience market in Australia
Bioscience market in Brazil
Bioscience in Africa
Life Sciences delivered revenue of £7.2 million (2013: £7.6 million) and a divisional operating profit of £1.1 million (2013: £1.2 million) as the Group invested to extend its market coverage and expand its specialist product offering. Source Bio Science’s ambition is to become Europe and the USA’s leading commercial provider of DNA sequencing and the Overnight Service™, which provides rapid access to sequencing data, is instrumental in achieving this. The Group’s market share in the UK continues to increase and DNA sequencing volumes during 2014 were over 30% greater than the prior year, driving both revenue and margin growth.
Healthcare revenue increased by 7% to £10.0 million (2013: £9.4 million) and divisional operating profit increased by 15% to £3.4 million (2013: £3.0 million).The diagnostic activities continued the impressive performance reported at the half year and the aggregate number of diagnostic tests conducted increased by over 70% compared with 2013.Bioscience 2015 was published in 2003. Today, nearly six years later, one is bound to have mixed reactions about what has been achieved by the UK bioscience sector. More worrying are the immediate prospects for what should be one of our high achieving, knowledge based industries. Senior people from Bioscience companies, Government Departments, Trade Associations, universities and research bodies have been involved in the Review and Refresh of Bioscience 2015. This report reflects the broad consensus of their views, though not necessarily those of the Government or Government officials, nor individuals, companies or organisations involved in the process.
A vision for bioscience
Over the five years since Bioscience 2015 was published, UK bioscience companies have struggled to achieve the vision it laid out, while other European companies have caught up with the UK in terms of projects in the pipeline. For example, in 2002 46% of the EU products in clinical trial development were in the UK. By 2007 this had reduced to 24% and analysis of the numbers of UK companies listed since 2002 shows that the number of companies with a market capitalisation of less than £25m has increased (see Market Capitalisation graph Fig 5) while the number of companies with a market capitalisation of more than £25 million has decreased. Therefore, although there may be a similar number of companies there is significantly less investment in those companies, preventing them from growing18 which is contrary to the hopes for the sector held in 2003. Therefore, there is a need for a more realistic vision given what is achievable in the time frame to 2015.
Increasing finance to bioscience SMEs: Government schemes
Government provides a number of schemes to support enterprises and is currently undertaking an exercise to simplify the support available. Businesses in all sectors will benefit from a simplified business support landscape, which will help them access the provision they need more easily. There are particular issues around the high risk of investing in bioscience, which have meant that the sector has not been able to fully benefit from some of the schemes.
In 2014, the European trend lines followed those in the US, albeit the trajectories for each of the key performance metrics did not reach the same heights. European biotech companies saw their revenue growth rebound strongly in 2014, as top-line sales expanded 15%, compared to the modest 3% uptick of 2013. In a sign of a healthier financial picture, 77% of European biotechs generated some revenue and 69% increased their top lines year over year. Those results are comparable to the revenue metrics posted by US biotech companies.
EU Clinical Trials Directive – Directive implemented in 2004 with the aim of patient protection, improved research reporting, harmonisation and increased competitiveness of European clinical research.
As in the US, European biotech companies’ aggregate net income increased by a healthy percentage, spiking 199% to US$3.3 billion. This percentage increase didn’t match the steep growth rate of 2013, when net income soared by 462%. It was also heavily influenced by the US$1.6 billion breakup fee Shire received from AbbVie when the proposed merger between the two companies was called off in October 2014.
Research and development undertaken by the bioscience sector is particularly expensive. R&D tax credits are a valuable source of Government support for the sector not least because they stimulate innovation. Bioscience companies are often loss making in their R&D phase, therefore a tax credit is much more favourable than a corporation tax cut which is of no benefit to such companies because there are no profits against which to levy the tax.
Adjusting for this one-time event, European biotech companies actually added US$533 million in aggregate net income in 2014, an annual increase of 52%. This increase was driven largely by strong performances by Medivir, Actelion and Amarin, which each increased their net income by at least US$90 million. Indeed, only 45% of European biotechs boosted their net income in 2014, compared to 50% in 2013. Among those with sizeable drops in net income were Meda and Jazz Pharmaceuticals, while Alkermes reported a net loss. Meda’s net income fell as a result of one-time restructuring charges related to its Rottapharm acquisition, while the bottom lines of both Jazz and Alkermes were affected by the aforementioned increases in their R&D budgets.
The market capitalizations of European biotech companies increased strongly for the second straight year amid positive investor sentiment. Indeed, market caps of European companies actually increased seven percentage points more than those in the US in 2014. A catch-up phenomenon was at least partly responsible, given that European biotech market valuations didn’t increase as dramatically in 2013 as those of US biotech’s, there was more room for a run-up in 2014. In all, 59% of European biotech saw their market caps increase in 2014.
Bioscience International Conferences invites all the participants from all over the world to attend 3rd Annual Congress on Bioscience October 16-17, 2017 Dubai, UAE, which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.
Bioscience is defined as technologies that relate to therapeutic or diagnostic products or services, including medical devices and digital health technologies that improve human health. Also included in the state definition are technologies that rely on research to improve agricultural output. As name “Bioscience” reflects belief that the study of biological systems is best approached by incorporating many perspectives. We bring together a diversity of disciplines that complement one another to unravel the complexity of biology. We incorporate the physical sciences, engineering, mathematics, computational and bioinformatics, and the social sciences, as appropriate, to problems we are addressing. We work with animals, plants and microorganisms and our research spans the levels of the biological hierarchy from molecules to ecosystems.
Bioscience International organizes a conference series of 1000+ Global Events inclusive of 300+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.
Why to attend???
This unique international conference provides a platform for researchers and decision makers in Bioscience to present their latest findings and learn about all the important developments in bioscience. Many scientists and world's renowned experts will participate in the conference. Throughout the course of the three days conference, you will have the opportunity to both network and hear leaders from the international academic and corporate bioscience communities.
The conference will attract a large group of scientists and researchers from round the globe. Delegates will have a valuable, informative and positive experience.
- Pharmaceutical Experts
- CEOs, CROs, directors and research associates from the bioscience industries
- Young Scientists
- Academic Students
- Bioscience Faculty
- Bioscience Counsellor’s
- Business Entrepreneurs